| 纯度 | >85% SDS-PAGE |
| 种属 | Human |
| 靶点 | CDCA8 |
| Uniprot No | Q53HL2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-280aa |
| 氨基酸序列 | MAPRKGSSRV AKTNSLRRRK LASFLKDFDR EVEIRIKQIE SDRQNLLKEV DNLYNIEILR LPKALREMNW LDYFALGGNK QALEEAATAD LDITEINKLT AEAIQTPLKS AKTRKVIQVD EMIVEEEEEE ENERKNLQTA RVKRCPPSKK RTQSIQGKGK GKRSSRANTV TPAVGRLEVS MVKPTPGLTP RFDSRVFKTP GLRTPAAGER IYNISGNGSP LADSKEIFLT VPVGGGESLR LLASDLQRHS IAQLDPEALG NIKKLSNRLA QICSSIRTHK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDCA8重组蛋白的虚构示例参考文献(仅供格式参考，实际文献请通过学术数据库查询)：
---
1. **标题**: "Functional Analysis of Recombinant CDCA8 in Mitotic Regulation"
**作者**: Zhang L, et al.
**摘要**: 本研究通过表达纯化CDCA8重组蛋白，揭示了其在染色体乘客复合体(CPC)中的关键作用。实验表明，CDCA8重组蛋白与Aurora B激酶直接互作，调控有丝分裂中染色体的正确分离，缺失会导致纺锤体组装异常。
2. **标题**: "Structural Characterization of CDCA8 and Its Role in Cancer Cell Proliferation"
**作者**: Tanaka K, et al.
**摘要**: 利用X射线晶体学解析CDCA8重组蛋白的三维结构，发现其N端结构域对结合Survivin至关重要。体外实验显示，CDCA8重组蛋白过表达促进肿瘤细胞增殖，提示其作为潜在抗癌靶点的价值。
3. **标题**: "CDCA8 Recombinant Protein Modulates DNA Damage Response in Hepatocellular Carcinoma"
**作者**: Wang Y, et al.
**摘要**: 通过构建CDCA8重组蛋白突变体，研究证实其通过p53信号通路调控肝癌细胞对DNA损伤的应答。抑制CDCA8重组蛋白活性可增强化疗药物敏感性。
4. **标题**: "Development of a CDCA8 Recombinant Protein-Based Diagnostic Assay for Early-Stage Tumors"
**作者**: Gupta R, et al.
**摘要**: 基于CDCA8重组蛋白的高特异性单克隆抗体制备，开发了一种新型ELISA检测方法，可在早期结直肠癌患者血清中检测CDCA8异常表达，灵敏度达85%。
---
注：以上内容为模拟文献，实际研究需参考PubMed、Web of Science等平台的真实论文。
**Background of CDCA8 Recombinant Protein**
CDCA8 (Cell Division Cycle Associated Protein 8), also known as Borealin, is a key regulatory protein involved in mitosis and chromosomal segregation. It is a member of the chromosomal passenger complex (CPC), alongside Survivin, Aurora B kinase, and INCENP. The CPC ensures accurate chromosome alignment, spindle assembly checkpoint regulation, and cytokinesis. CDCA8 plays a critical role in stabilizing the complex and targeting Aurora B kinase to specific mitotic structures, such as centromeres and the central spindle.
CDCA8 is highly expressed in proliferating cells, particularly during the G2/M phase of the cell cycle. Dysregulation of CDCA8 is linked to genomic instability, mitotic errors, and carcinogenesis. Overexpression of CDCA8 has been observed in various cancers, including breast, lung, and colorectal cancers, correlating with poor prognosis, tumor progression, and chemotherapy resistance. This makes it a potential diagnostic marker and therapeutic target.
Recombinant CDCA8 protein is engineered using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His or GST) for purification and detection. It retains native structural and functional properties, enabling studies on its interactions with CPC components, enzymatic activity assays (e.g., Aurora B kinase activation), and screening of inhibitors. Additionally, recombinant CDCA8 is used to generate antibodies, study mitotic mechanisms in vitro, and explore its role in cancer biology through overexpression or knockdown models.
Overall, CDCA8 recombinant protein serves as a vital tool for dissecting mitotic regulation, cancer research, and developing targeted therapies.
×
